主要目的：以湖南迪诺制药股份有限公司的奥利司他胶囊（规格：60mg）为受试制剂，以GlaxoSmithKline Consumer Healthcare的奥利司他胶囊（规格：60mg，商品名：Alli®）为参比制剂。考察两种奥利司他胶囊的药效学差异。评价两制剂生物等效性。次要目的：观察多次服用奥利司他胶囊在健康研究参与者中的安全性。

[Translation]

Primary objective: Orlistat capsules (specification: 60 mg) of Hunan Dino Pharmaceutical Co., Ltd. were used as the test preparation, and orlistat capsules (specification: 60 mg, trade name: Alli®) of GlaxoSmithKline Consumer Healthcare were used as the reference preparation. The pharmacodynamic differences between the two orlistat capsules were investigated. The bioequivalence of the two preparations was evaluated. Secondary objective: To observe the safety of repeated use of orlistat capsules in healthy study participants.

Start Date10 Jul 2025

Sponsor / Collaborator

Hunan Dinuo Pharmaceutical Co. Ltd.

NCT06854614

/ RecruitingPhase 4IIT

Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

This is a prospective, pragmatic, 21 month, single-center, randomized, 2-phased, open-label, parallel-group trial comparing the use of enhanced lifestyle changes (ELC) in two different sequential anti obesity medication (AOM) therapies. The ELC consists of a medically-supervised and comprehensive weight loss program (Cleveland Clinic's Department of Endocrinology, Diabetes and Metabolism's Integrated Weight Management Program). In the first phase (9 months) of the study, all participants will receive tirzepatide 15 mg (option #1) or semaglutide 2.4 mg if tirzepatide is not tolerated. In the second phase, after completing 9 months of tirzpeatide or semaglutide, participants will continue ELC and will be randomly assigned to a different oral AOM therapy for another 12 months: group 1 (phentermine-topiramate or naltrexone-bupropion) or group 2 (orlistat).
The primary endpoint will be the percentage weight loss at 21 months compared to weight loss at 9 months. The goal will be to show superiority of the arm receiving ELC plus AOM therapy (phentermine-topiramate or naltrexone-bupropion) when compared to the other AOM therapy group (orlistat). Secondary and exploratory endpoints will include percentage of fat mass loss, lean muscle mass, functional capacity, muscle strength and compliance to enhanced lifestyle changes. Informed consent will be obtained. IRB approval of the study will be obtained.

Start Date01 Mar 2025

Sponsor / Collaborator

The Cleveland Clinic Foundation

NCT06818955

/ Not yet recruitingPhase 2IIT

Clinical Study on the Safety and Efficacy of Orlistat in Third-generation EGFR-TKI Resistance

EGFR mutation positivity accounts for 50% of lung adenocarcinoma cases. Multiple clinical trials, represented by FLAURA, AENEAS, and FURLONG studies, have confirmed that third-generation EGFR-TKI can provide significant benefits to patients with EGFR sensitive mutations and has become the first-line preferred treatment for EGFR mutation positive NSCLC, with a median PFS of around 19 and OS of around 38 months. These large-scale Phase III studies have confirmed the excellent efficacy of third-generation EGFR-TKI in EGFR mutation positive patients. However, regardless of the targeted drug, resistance will occur within less than 2 years. Blood test data for first-line treatment with osimertinib showed that the most common forms of resistance were secondary MET amplification (20%), EGFR C797S mutation (8%), PIK3CA, Her-2 amplification, and so on. The mechanism of resistance is complex and has many factors. Currently, for the treatment of third-generation EGFR-TKI resistance, the IMPOWER150 and ORIENTAL31 treatment modes are commonly used. Although the combination of these four drugs has good efficacy, the side effects are significant. Some patients are unwilling to undergo chemotherapy due to physical problems and hope to continue taking targeted drugs orally. Orlistat is a long-acting and potent specific gastrointestinal lipase inhibitor that can directly block the absorption of body fat. It is commonly used for weight loss in clinical practice and is relatively inexpensive. Our project team found in vitro and in vivo data that orlistat can effectively promote sensitivity to osimertinib. The combination of orlistat and osimertinib can overcome osimertinib resistance without significant toxic side effects. For patients who are unwilling to undergo chemotherapy and require continued oral targeted therapy, the investigators attempted to add orlistat to see if it can improve resistance.

Start Date16 Feb 2025

Sponsor / Collaborator

Hubei Cancer Hospital

100 Clinical Results associated with Orlistat

100 Translational Medicine associated with Orlistat

100 Patents (Medical) associated with Orlistat

2,846

Literatures (Medical) associated with Orlistat

31 Dec 2025·CANCER BIOLOGY & THERAPY

NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia

Article

Author: Chen, Yanling ; Pan, Jian ; Jiao, Wanyan ; Wu, Di ; Cheng, Jia ; Yu, Juanjuan ; Su, Xin ; Xiao, Peifang ; Gao, Yuqing ; Fei, Danhong ; Li, Xiaolu ; Zhang, Zimu ; Zhu, Qing ; Cai, Linbo

Cell cycle dysregulation and the corresponding metabolic reprogramming play significant roles in tumor development and progression. CDK9, a kinase that regulates gene transcription and cell cycle, also induces oncogene transcription and abnormal cell cycle in AML cells. The function of CDK9 for gene regulation in AML cells requires further exploration. In this study, we knocked down the CDK9 to investigate its effects on the growth and survival of AML cells. Through RNA-seq analysis, we identified that in U937 cells CDK9 regulates numerous genes involved in proliferation and apoptosis, including mTOR, SREBF1, and Bcl-2. Furthermore, our results demonstrated that both CDK9 and FASN are crucial for the proliferation and survival of Kasumi-1 and U937 cells. Mechanistically, MCL1, c-Myc, and Akt/mTOR/SREBF1 may be critical factors and pathways in the combined therapy of NVP-2 and Orlistat. In summary, our study revealed that CDK9 and FASN are vital for maintaining AML cell survival and proliferation. Treatment with NVP-2 and Orlistat may be a promising clinical candidate for patients with AML.

01 Dec 2025·FOOD CHEMISTRY

Metabolomic insights into antioxidant properties of blueberry (Vaccinium croymbosum) leaves and a preliminary exploration of their in vitro lipid-lowering activity

Article

Author: Li, Dongnan ; Wang, Li ; Tian, Qilin ; He, Ying ; Yang, Xuefeng ; Wang, Jiaxin ; Tian, Jinlong ; Li, Bin ; Gao, Ningxuan ; Wang, Liang

In this study, the metabolite differences and antioxidant and in vitro lipid-lowering activities of Vaccinium corymbosum "Lanmei 1" leaves from six different regions in China were evaluated. Integrated untargeted metabolomics and antioxidant assays identified Zhejiang-sourced leaves (ZJ-1) as optimal, demonstrating exceptional phenolic (267.72 mg/g), flavonoid (708.33 mg/g), and proanthocyanidin (422.81 mg/g) contents. Metabolomic profiling detected 1968 compounds, with flavonoid derivatives driving ZJ-1's superior antioxidant capacity. In cellular hyperlipidemia models, ZJ-1 extract exhibited dose-dependent lipid clearance, while pancreatic lipase (PL) inhibition assays revealed an IC₅₀ of 6.054 mg/mL versus orlistat (0.3518 mg/mL). Molecular docking confirmed stronger binding affinities of ZJ-1's primary constituents-chlorogenic acid (-9.758 kcal/mol) and quercetin (-9.192 kcal/mol)-to PL catalytic residues compared to orlistat (-5.271 kcal/mol). These results establish blueberry leaves as dual-functional antioxidant-hypolipidemic resources, with geographic origin critically modulating phytochemical profiles. This research advances the application of underutilized leaf biomass for nutritional healthcare.

01 Dec 2025·JOURNAL OF PHARMACEUTICAL SCIENCES

Anti-obesity effects of novel topiramate-ferulic acid conjugate nanocrystals in high-fat diet-induced obese C57BL6/J mice

Article

Author: Banerjee, Biswajit ; Kar, Biswakanth ; Sharma, Tripti ; Padhy, Ipsa ; Mohapatra, Sujata

Curbing the enzymatic action of human pancreatic lipase has emerged as an effective strategy for designing and developing anti-obesity medications. We reported the 2D QSAR based design, synthesis and biological evaluation of novel Topiramate-phenolic acid conjugates in our previous work. Among the synthesized conjugates, T4 displayed potent pancreatic lipase inhibition as well as antioxidant property. Although, low aqueous solubility of T4 raised concerns regarding its further development into an orally active antiobesity drug candidate. To address the poor water solubility and hence to alleviate bioavailiblity concerns, in the current study we focused on the fabrication of nanocrystals of pure conjugate T4. The fabricated nanocrystals were characterised by FTIR, XRD, DSC, SEM along with particle size analysis. Further, tin vitro dissolution was carried out to study he drug release pattern in PBS (pH 6.8). The anti-obesity effect of T4NC was investigated in HFD-induced obese male C57BL6/J mice model in a 14-week study period. A reduction in crystalline nature of T4NC nanocrystals was evident from the PXRD and DSC analysis. The nanocrystals displayed enhanced dissolution as depicted by about 75 % cumulative drug release in contrast to only 39 % cumulative drug release from the parent conjugate. Administration of T4NC nanocrystals in HFD induced obese mice reduced increased body weight, feed intake, food efficiency ratio and organ weights. Elevated levels of serum TG, TC, LDL-C, AST and ALT were reduced to normal, while reduced HDL-C levels were improved in T4NC treated mice. T4NC nanocrystals administration in obese mice also ameliorated high fat diet induced insulin resistance as observed from the HOMA-IR values. High lipid percentage in fecal matter of mice treated with T4NC indicated decreased catalytic activity of pancreatic lipase leading to reduced dietary lipid digestion and absorption. Furthermore, gene expression studies revealed the inhibitory effect of T4NC on adipocyte differentiation via downregulating PPARγ expression. The antiobesity effects of T4NC nanocrystals were significantly higher (p < 0.05) than the conventional lipase inhibitor orlistat. Conclusively, the results of the study warranty the development of novel T4NC nanocrystals as potential antiobesity medication.

News (Medical) associated with Orlistat

22 Aug 2025

·pharma.economictimes.indiatimes.com

GLP-1 drugs linked to lower cancer risks

London: GLP-1 drugs for diabetes and weight loss may influence patients' cancer risk , usually lowering it but sometimes possibly increasing it, new findings suggest. U.S. researchers reviewed 10 years of medical records from 43,317 users and 43,315 similar nonusers of Novo Nordisk 's type 2 diabetes drugs Victoza and Ozempic or its weight-loss medication Wegovy , or Eli Lilly's Mounjaro for diabetes or Zepbound for weight loss. All volunteers were at risk for obesity-related cancers. Each year, out of every thousand participants, 13.6 users of GLP-1 drugs were diagnosed with any of 14 types of cancer, compared to 16.6 nonusers, the researchers reported in JAMA Oncology. After accounting for individual risk factors, the overall cancer risk was 17 per cent lower in GLP-1 users. In particular, GLP-1 use was associated with a 25 per cent lower risk of endometrial cancer , a 47 per cent lower risk of ovarian cancer and a 31 per cent lower risk of meningioma. GLP-1 drugs were also associated with a slight increase in risk for kidney cancer. The increase was not statistically significant, meaning it could have been due to chance - but an earlier study also found a higher risk of kidney cancer with use of GLP-1 drugs for diabetes, the authors note. Observational studies like this one cannot prove cause and effect, and it's impossible to know whether any reductions in cancer risk were due to the GLP-1 drugs themselves or to drug-induced weight loss. Still, the researchers said, "Given that more than 137 million individuals in the U.S. are currently eligible for GLP-1 therapies, even modest changes in cancer risk could have substantial public health implications." CONDENSING HOURS-LONG IV INFUSIONS INTO QUICK INJECTIONS New technology may allow quick injections of drugs that currently require slow intravenous infusions, researchers say. The high volume of fluid required to administer so-called antibody drugs - often used for cancer, autoimmune diseases and metabolic disorders - means patients must submit to time-consuming intravenous drips. That's because the antibodies, which are proteins, only remain stable in fluids at low concentrations. A new method of coating the proteins, however, allows them to be stored in the high concentrations necessary for administration with a standard syringe or autoinjector device, researchers reported in Science Translational Medicine. To pack the proteins into liquid at high concentrations but keep them stable and functional, the researchers encased tiny particles in a substance they developed called MoNi. The coating prevents particles from dissolving or sticking together in fluid and keeps them dry and stable, the researchers said. "We ended up with something that looks like a candy-coated chocolate, where the protein is on the inside and our special polymer forms a solid, glassy coating on the outside," study leader Eric Appel of Stanford University said in a statement. In tests using three different proteins - albumin, human immunoglobulin and a monoclonal antibody treatment for COVID - the researchers were able to inject a solution with more than double the concentration of typical liquid injections. The new method "potentially works with any biologic drug, so that we can inject it easily," Appel said. "That takes these treatments from a several-hour ordeal at a clinic with an IV infusion to something you can do in seconds with an autoinjector at your house," Appel said. BOBA TEA-LIKE BEADS BEING DEVELOPED FOR WEIGHT LOSS Plant-based microbeads resembling boba tea pearls helped rats lose weight on a high-fat diet and may one day become an option for drug-free weight loss, Chinese researchers say. The microbeads are made from green tea and vitamin E, then coated with molecules derived from seaweed. Once ingested, the coating expands, and the green tea molecules and vitamin E bind to and trap partially digested fats in the intestine. Rats on a high fat diet lost 17 per cent of their total body weight when they also consumed the microbeads for a month, while rats fed the high-fat diet but without the microbeads didn't lose weight. The rats fed the microbeads also had less liver damage than rats fed the high-fat diet without microbeads, the researchers found. The microbead group excreted the same amount of fat in their stool as another group of rats on a high-fat diet who received the weight-loss drug orlistat, which also works to remove partly digested fat in the intestines - but without the gastrointestinal side effects seen in the orlistat group. Orlistat is sold over the counter as Alli by GlaxoSmithKline and by prescription as Xenical by Roche. The researchers will present their results at the American Chemical Society Fall 2025 Digital Meeting. In the meantime, they have begun to test the microbeads in humans. The beads are nearly flavorless and could be easily integrated into people's diets, the researchers say. "We want to develop something that works with how people normally eat and live," study leader Yue Wu, a graduate student at Sichuan University, said in a statement. (Reporting by Nancy Lapid; Editing by Mark Porter)

Clinical Result

16 Oct 2024

·www.biospace.com

As Sanofi Preps Consumer Healthcare Sale, Here’s a Look Back at Similar High-Profile Deals

iStock, master1305 Sanofi looks to follow a deep history of Big Pharmas offloading their consumer healthcare businesses. When Sanofi announced last week that it plans to sell a 50% controlling stake of Opella, its consumer helath business, the disclosure echoed similar moves by other Big Pharma companies, including Johnson & Johnson, GSK, Pfizer and Novartis. Just last year, J&J split off Kenvue, creating a standalone company to house iconic brands like Tylenol and Benadryl. Novartis did the same with its generics and biosimilars unit Sandoz as well. But if you look back even further, Roche was the first Big Pharma 20 years ago to portion off its consumer work and hand it off to Bayer. Sanofi is now looking to make a similar move, selling Opella to a private equity firm. The company first set up its consumer healthcare section as a standalone global business unit in 2019, seemingly prepping it for a full spin out at some point, while streamlining down to only priority brands. Those under the Opella banner include seasonal allergy medication Allegra, topical pain relief line IcyHot and constipation drug DulcoLax. As of 2023, the unit had revenue of €5.2 billion ($5.7 billion), with a presence in 150 countries with 11,000 employees. Sanofi telegraphed the split from the consumer healthcare unit a year ago as part of its October 2023 “Play to Win Strategy.” Specifically, the company announced a plan to separate the consumer business entirely and shift its focus to innovative medicines and vaccines. The move would create two separate entities, “each better equipped to pursue its own business strategy,” according to the release, which noted that the separation could happen by the fourth quarter of 2024. And here we are, the final quarter just beginning, and Sanofi is in earnest talks with a potential buyer for Opella. As we wait for that story to unfold, BioSpace takes a look back at how this sort of transaction has gone previously. Kenvue Former parent: Johnson & Johnson New ownership: Standalone company Date of split: August 23, 2023 Brands: Tylenol, Zyrtec, Nicorette, Benadryl, Motrin 2023 revenue: $15.4 billion YOY growth: 5% Kenvue spun out of J&J in August 2023, marking a “historic moment,” according to newly-minted CEO Thibaut Mongon. J&J still has a stake in the company, but Kenvue is otherwise independent . A debt offering and the IPO raised $13.2 billion. When announcing the spin off, J&J CEO Joaquin Duato said the separation “sharpens” the healthcare company’s focus on innovation in pharma and medtech. The separate company is now the largest pure-play consumer health company by revenue, known for brands such as Tylenol, Neosporin, Johnson’s baby soap, Listerine and Neutrogena. Kenvue planned to spend 2024 investing in its brands and boosting prominence on store shelves. Mongon said during a second-quarter earnings call, “Earlier this year, I committed to you that you would see a new Kenvue, the bolder company that is moving quickly to advance our three priorities to reach more consumers effectively, invest further behind our brands, and build a culture of performance and impact.” Sandoz Former parent: Novartis New ownership: Standalone company Date of split: October 4, 2023 Brands: Generics, biosimilars 2023 revenue: $9.6 billion (reported as net sales) YOY growth: 11% Wanting to focus 100% on innovative medicines , Novartis spun off the Sandoz unit, which manufactures generics and biosmiliars, just over a year ago. This transaction was a little different from the others on this list, as Sandoz exclusively manufactures prescription medicines, but it gets lumped in with the rest when talking about major pharmaceutical companies calving off massive portions of their business to focus on innovation. In 2023, Sandoz launched biosimilars for AbbVie’s Humira and J&J’s Stelara. This year, it’s launched a generic for chemotherapy drug paclitaxel and a biosimilar of Regeneron’s Eylea, among many others. CEO Richard Saynor boasted during a second-quarter earnings call in August that Sandoz had grown for the 11th straight quarter. But he also foreshadowed changes that could impact employees, with a multiyear program underway to reduce costs by $200 million annually by 2026. “Coming out of a large pharmaceutical company with a much more complex and layered infrastructure we have plans to reduce layers across the organization and simplify our processes,” Saynor said. Haleon Former parent: GSK/Pfizer New ownership: Standalone company Date of split: July 18, 2022 Brands: Sensodyne, Advil, Voltaren, Theraflu, Centrum 2023 revenue: £11.3 billion ($14.7 billion) YOY growth: 4.1% GSK’s consumer healthcare unit was said to be worth $36 billion at the time of the demerger, which was announced in early 2022. CEO Emma Walmsley said the spin out was coming as the U.K. pharma planned “the most significant corporate change for GSK in the last 20 years.” The unit was formed through a series of M&A deals and divestments, and was partly owned by Pfizer at the time of the sale. GSK held a majority 68% interest while Pfizer had 32%. Brian McNamara, previously the chief of the consumer division at GSK, was put in place as CEO, a role he still holds. Haleon recently upped its stake in a Chinese joint venture called Tianjin TSKF Pharmaceutical, adding another 33% equity interest, and divested ChapStick and other brands, along with a handful of nicotine replacement products. “We love the portfolio we have. We don’t believe we need to do anything with the portfolio to deliver on our guidance that we have given. But that said, we want to proactively and actively manage the portfolio,” McNamara said. He promised that as certain products are offloaded, his team is keeping an eye out for bolt-on M&A opportunities. Both GSK and Pfizer have been lowering their stakes in Haleon in recent months, with Pfizer’s share dropping from 32% to 24% in March, while GSK’s has fallen to just 4.2% ownership. Consumer health business Former parent: Merck KGaA New ownership: Proctor & Gamble Date of split: December 1, 2018 Brands: Neurobion, Nasivin, Bion3 2023 revenue: N/A YOY growth: N/A Germany’s Merck KGaA sold off its consumer health unit to Proctor & Gamble in 2018, perhaps kickstarting the more recent trend we see today. The unit was purchased for €3.4 billion ($3.7 billion), netting €2.7 billion ($2.9 billion) in cash, which Merck put towards reducing debt. The unit’s key brands include Neurobion, Dolo-Neurobion, Femibion, Nasivin and Bion3, primarily sold in Europe, Latin America and Asia. P&G also took on the Merck employees from the unit. P&G has previously had a joint venture with Teva in consumer health, which was terminated with the Merck deal. Roche Consumer Health Former parent: Roche Holdings New ownership: Bayer Date of split: July 2004 Brands: Aleve, Bepanthen, Berocca, Flanax, Redoxon 2023 revenue: N/A YOY growth: N/A Roche and Bayer had been working together in a consumer health joint venture, but the Swiss pharma decided to leave the partnership in 2004. Bayer was happy to pick up the remaining shares plus a few more assets including manufacturing sites. The complex transaction was three deals in one, with the termination of the joint venture, the sale of Roche’s over-the-counter business to Bayer and the out-licensing of an anti-obesity drug called orlistat going to GSK. Consider that, 20 years later, obesity and weight loss has become all the rage in pharma, with Roche investing heavily in the GLP-1 space to keep pace with its peers. Orlistat is still manufactured and sold over-the-counter by none-other than GSK’s former consumer unit Haleon and also as a generic by others.

AcquisitionExecutive ChangeLicense out/in

21 Aug 2024

·www.drugs.com

Semaglutide-Linked Suicidal Ideation ID'd in Disproportionality Analysis

WEDNESDAY, Aug. 21, 2024 -- Semaglutide -associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open . Georgios Schoretsanitis, M.D., Ph.D., from Northwell Health in Glen Oaks, New York, and colleagues examined potential signals for suicidal and self-injurious adverse drug reactions (ADRs) associated with the glucagon-like peptide 1 receptor agonists semaglutide and liraglutide in a disproportionality analysis. Participants were patients experiencing an ADR, which was suspected as attributable to semaglutide or liraglutide. Overall, 107 and 162 cases of suicidal and/or self-injurious ADRs were reported between November 2000 and August 2023 for semaglutide and liraglutide, respectively. The researchers detected significant disproportionality for semaglutide-associated suicidal ideation (reporting odds ratio, 1.45), which remained significant for those coreporting antidepressant and benzodiazepine use (reporting odds ratios, 4.45 and 4.07, respectively) and compared with dapagliflozin, metformin, and orlistat (reporting odds ratios, 5.56, 3.86, and 4.24, respectively). "We reported a disproportionality signal of suicidal ideation with semaglutide, but not for liraglutide, particularly among patients with coreported antidepressant use, a proxy for affective disorders (a notable exclusion criteria of premarketing clinical trials)," the authors write. One author disclosed ties to the biopharmaceutical industry. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

100 Deals associated with Orlistat

External Link

KEGG	Wiki	ATC	Drug Bank
D04028	Orlistat	A08AB01	DB01083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	European Union	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Obesity	Iceland	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Obesity	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Obesity	Norway	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Overweight	European Union	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Overweight	Iceland	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Overweight	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998
Overweight	Norway	CHEPLAPHARM Arzneimittel GmbH	29 Jul 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic Diseases	Phase 3	Russia	Hoffmann-La Roche, Inc.	01 Apr 2008
Familial chylomicronaemia syndrome	Phase 2	United States	The University of Texas Southwestern Medical Center	26 Jan 2024
Hypertriglyceridemia	Phase 2	United States	The University of Texas Southwestern Medical Center	01 Dec 2015
Hyperlipoproteinemia Type I	Phase 2	United States	The University of Texas Southwestern Medical Center	01 Nov 2015
Diabetes Mellitus	Phase 2	United States	Roche Pharma AG	01 May 1998
Hypertension	Phase 2	United States	Roche Pharma AG	01 May 1998
Sleep Apnea Syndromes	Phase 2	United States	Roche Pharma AG	01 May 1998

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04531176 (EMPOWER-T2D, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Obesity	74	Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM)	vppqorgmxv(lfljpizukt) = oeqrlrlabb wjnefytqqo (khoifcsyet, xuhxlevbid - imfctpfnke) View more	-	22 Jul 2024
				Weight Management Program (WMP) (Obesity-centric Approach Without AOM)	vppqorgmxv(lfljpizukt) = pwnjmdtjop wjnefytqqo (khoifcsyet, zlziakhklc - taoryopzug) View more
NCT05496075 (ADA2024) Manual	Phase 3	Hyperuricemia \| Obesity	72	Orlistat	ssddxdcrhz(hfxyogctmd): HR = 0.31 (95% CI, 0.11 - 0.85), P-Value = 0.023	Positive	24 Jun 2024
				Placebo
NCT03582722 (CTgov)	Phase 4	Poisoning	100	Multivitamin (Placebo)	utrgwjkvsw(rktfagfegx) = cqwybmwwmf ipcafdapuz (qhfpovqqzs, 16.4) View more	-	25 Apr 2024
				Multivitamin+Orlistat (Orlistat Weight Loss Aid)	utrgwjkvsw(rktfagfegx) = ifjkjnxkye ipcafdapuz (qhfpovqqzs, 17.8) View more
NCT05496075 (Pubmed \| Lipids Health Dis) Manual	Phase 4	Hyperuricemia \| Overweight \| Obesity	72	Orlistat	ismhohjnjt(sjhpjefdth) = There was no significant difference in SUA level between the two groups wlotesdcev (opvtipnrly ) View more	Positive	11 Mar 2024
				Placebo
NCT01351753 (REVIVE, CTgov)	Phase 2	Metabolic Syndrome \| Obesity, Abdominal	136	Metformin (Metformin)	qxijvxlung(wcngdqameu) = keahnyqukd xjqltrsdmi (acdrxewtgx, yillbcxesj - ljhzgogtxd) View more	-	09 Jun 2021
				Orlistat+Metformin (Metformin + Orlistat)	qxijvxlung(wcngdqameu) = fbbfjdltmq xjqltrsdmi (acdrxewtgx, pvtcntfquq - awedfsjbfn) View more
ChiCTR-IPR-17011629 (Pubmed \| J Clin Endocrinol Metab)	Not Applicable	Overweight \| Obesity	877	Orlistat	tklcwbcbqn(jmsezqufxv) = cqrpiobjxz ktbdiavlvc (aszodcuvtg ) View more	Negative	15 May 2021
				Placebo	tklcwbcbqn(jmsezqufxv) = husqqtgpmz ktbdiavlvc (aszodcuvtg ) View more
NCT02432209 (FIT-PLESE, CTgov)	Phase 3	Infertility, Female \| Obesity	379	Moderate physical activity+Orlistat (Intensive Lifestyle Mod. Intervention)	dpiipyastn = zifcliylsl brdeylilsz (axmvbdtamr, obfsuowzsz - jfyulouhqf) View more	-	15 Mar 2021
				Moderate physical activity (Standard Lifestyle Intervention)	dpiipyastn = wjciiydljq brdeylilsz (axmvbdtamr, kjlzfvzidx - hbwjeeepzh) View more
NCT02529631 (Pubmed)	Not Applicable	Overweight \| Obesity	64	Orlistat 60mg	klafzavfhr(mpttjzbokc) = ihjrgncxxw aomierygbq (kqhkzrkpsx )	-	01 Jan 2017
				Polyglucosamine	klafzavfhr(mpttjzbokc) = fubptuhstd aomierygbq (kqhkzrkpsx )
NCT01035333 (CTgov)	Phase 4	Weight Loss \| Obesity	19	Orlistat	nnibywdftj(pndvpswskw) = uhaaipdtyq ikdrjtmbls (feypkujvzr, 3.4) View more	-	04 Apr 2014
NCT00601354 (CTgov)	Not Applicable	Binge-Eating Disorder \| Overweight	17	OTC Orlistat (OTC Orlistat + Guided Self-help Affect Regulation)	rualvkeqbg(ahqateurvl) = xxpfhzljvo somtyjybab (isutnqtajv, 14.36) View more	-	09 Sep 2013
				Orlistat (OTC Orlistat /Medication Management Alone)	rualvkeqbg(ahqateurvl) = bkyrugcjbh somtyjybab (isutnqtajv, 8.11) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis